Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction with Big Pharma partnerships. TEM's differentiated model leverages AI-driven diagnostics and data licensing, generating immediate revenues rather than relying on speculative milestone payments. Strategic acquisition of Personalis positions TEM to capitalize on the rapidly expanding minimal residual disease (MRD) cancer testing market.